{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:18:05Z","timestamp":1790763485157,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Extracorporeal photochemotherapy (ECP) is employed for the management of cutaneous T cell lymphoma (CTCL). ECP involves the extracorporeal exposure of white blood cells (WBCs) to a photosensitizer, 8-methoxypsoralen (8-MOP), in the context of ultraviolet A (UVA) radiation, followed by WBC reinfusion. Historically, the therapeutic activity of ECP has been attributed to selective cytotoxicity on circulating CTCL cells. However, only a fraction of WBCs is exposed to ECP, and 8-MOP is inactive in the absence of UVA light, implying that other mechanisms underlie the anticancer effects of ECP. Recently, ECP has been shown to enable the physiological differentiation of monocytes into dendritic cells (DCs) that efficiently cross-present tumor-associated antigens (TAAs) to CD8\n                    <jats:sup>+<\/jats:sup>\n                    T lymphocytes to initiate cognate immunity. However, the source of TAAs and immunostimulatory signals for such DCs remains to be elucidated. Here, we demonstrate that 8-MOP plus UVA light reduces melanoma cell viability along with the emission of ICD-associated danger signals including calreticulin (CALR) exposure on the cell surface and secretion of ATP, high mobility group box 1 (HMGB1) and type I interferon (IFN). Consistently, melanoma cells succumbing to 8-MOP plus UVA irradiation are efficiently engulfed by monocytes, ultimately leading to cross-priming of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells against cancer. Moreover, malignant cells killed by 8-MOP plus UVA irradiation in vitro vaccinate syngeneic immunocompetent mice against living cancer cells of the same type, and such a protection is lost when cancer cells are depleted of calreticulin or HMGB1, as well as in the presence of an ATP-degrading enzyme or antibodies blocking type I IFN receptors. ECP induces bona fide ICD, hence simultaneously providing monocytes with abundant amounts of TAAs and immunostimulatory signals that are sufficient to initiate cognate anticancer immunity.\n                  <\/jats:p>","DOI":"10.1038\/s41419-019-1819-3","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T19:05:12Z","timestamp":1564686312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Extracorporeal photochemotherapy induces bona fide immunogenic cell death"],"prefix":"10.1038","volume":"10","author":[{"given":"Kazuki","family":"Tatsuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-0729","authenticated-orcid":false,"given":"Patrick","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Sobolev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alp","family":"Yurter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rivera-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Edelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"1819_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM198702053160603","volume":"316","author":"R Edelson","year":"1987","unstructured":"Edelson, R. et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N. Engl. J. Med. 316, 297\u2013303 (1987).","journal-title":"N. Engl. J. Med"},{"key":"1819_CR2","first-page":"519","volume":"58","author":"FP Gasparro","year":"1985","unstructured":"Gasparro, F. P., Chan, G. & Edelson, R. L. Phototherapy and photopharmacology. Yale J. Biol. Med. 58, 519\u2013534 (1985).","journal-title":"Yale J. Biol. Med."},{"key":"1819_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2017.04.006","volume":"66","author":"I Vitale","year":"2017","unstructured":"Vitale, I., Manic, G., De Maria, R., Kroemer, G. & Galluzzi, L. DNA damage in stem cells. Mol. Cell 66, 306\u2013319 (2017).","journal-title":"Mol. Cell"},{"key":"1819_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1751-1097.1996.tb05657.x","volume":"63","author":"R Johnson","year":"1996","unstructured":"Johnson, R. et al. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem. Photobio. 63, 566\u2013571 (1996).","journal-title":"Photochem. Photobio."},{"key":"1819_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486\u2013541 (2018).","journal-title":"Cell Death Differ."},{"key":"1819_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1073\/pnas.84.1.246","volume":"84","author":"S Yemul","year":"1987","unstructured":"Yemul, S. et al. Selective killing of T lymphocytes by phototoxic liposomes. Proc. Natl Acad. Sci. USA 84, 246\u2013250 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1819_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/1523-1747.ep12329711","volume":"107","author":"EK Yoo","year":"1996","unstructured":"Yoo, E. K., Rook, A. H., Elenitsas, R., Gasparro, F. P. & Vowels, B. R. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 107, 235\u2013242 (1996).","journal-title":"J. Invest. Dermatol"},{"key":"1819_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.transci.2013.07.031","volume":"50","author":"RL Edelson","year":"2014","unstructured":"Edelson, R. L. Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. Transfus. Apher. Sci. 50, 322\u2013329 (2014).","journal-title":"Transfus. Apher. Sci."},{"key":"1819_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0190-9622(92)70212-X","volume":"27","author":"P Heald","year":"1992","unstructured":"Heald, P. et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J. Am. Acad. Dermatol. 27, 427\u2013433 (1992).","journal-title":"J. Am. Acad. Dermatol"},{"key":"1819_CR10","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/blood-2009-11-256040","volume":"116","author":"C Berger","year":"2010","unstructured":"Berger, C. et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 116, 4838\u20134847 (2010).","journal-title":"Blood"},{"key":"1819_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.transci.2013.11.008","volume":"50","author":"TS Durazzo","year":"2014","unstructured":"Durazzo, T. S. et al. Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. Transfus. Apher. Sci. 50, 370\u2013378 (2014).","journal-title":"Transfus. Apher. Sci."},{"key":"1819_CR12","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1158\/0008-5472.CAN-18-0171","volume":"78","author":"A Ventura","year":"2018","unstructured":"Ventura, A. et al. Extracorporeal photochemotherapy drives monocyte-to-dendritic cell maturation to induce anticancer immunity. Cancer Res 78, 4045\u20134058 (2018).","journal-title":"Cancer Res"},{"key":"1819_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.transci.2016.06.001","volume":"55","author":"N Kibbi","year":"2016","unstructured":"Kibbi, N., Sobolev, O., Girardi, M. & Edelson, R. L. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. Transfus. Apher. Sci. 55, 146\u2013152 (2016).","journal-title":"Transfus. Apher. Sci."},{"key":"1819_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"1819_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med 13, 54\u201361 (2007).","journal-title":"Nat. Med"},{"key":"1819_CR16","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/blood-2016-08-731737","volume":"128","author":"J Fucikova","year":"2016","unstructured":"Fucikova, J. et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood 128, 3113\u20133124 (2016).","journal-title":"Blood"},{"key":"1819_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med 15, 1170\u20131178 (2009).","journal-title":"Nat. Med"},{"key":"1819_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nature08296","volume":"461","author":"MR Elliott","year":"2009","unstructured":"Elliott, M. R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282\u2013286 (2009).","journal-title":"Nature"},{"key":"1819_CR19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med 13, 1050\u20131059 (2007).","journal-title":"Nat. Med"},{"key":"1819_CR20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med 20, 1301\u20131309 (2014).","journal-title":"Nat. Med"},{"key":"1819_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2018.05.013","volume":"34","author":"C Vanpouille-Box","year":"2018","unstructured":"Vanpouille-Box, C., Demaria, S., Formenti, S. C. & Galluzzi, L. Cytosolic DNA Sensing in Organismal Tumor Control. Cancer Cell 34, 361\u2013378 (2018).","journal-title":"Cancer Cell"},{"key":"1819_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fimmu.2015.00402","volume":"6","author":"J Fucikova","year":"2015","unstructured":"Fucikova, J. et al. Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front. Immunol. 6, 402 (2015).","journal-title":"Front. Immunol."},{"key":"1819_CR23","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1172\/JCI45401","volume":"121","author":"H Zischka","year":"2011","unstructured":"Zischka, H. et al. Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J. Clin. Invest 121, 1508\u20131518 (2011).","journal-title":"J. Clin. Invest"},{"key":"1819_CR24","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1158\/0008-5472.CAN-12-3000","volume":"73","author":"J Michels","year":"2013","unstructured":"Michels, J. et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 73, 2271\u20132280 (2013).","journal-title":"Cancer Res."},{"key":"1819_CR25","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691 (2014).","journal-title":"Oncoimmunology"},{"key":"1819_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg, A. D. et al. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6, e1386829 (2017).","journal-title":"Oncoimmunology"},{"key":"1819_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature19364","volume":"537","author":"R Eil","year":"2016","unstructured":"Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539\u2013543 (2016).","journal-title":"Nature"},{"key":"1819_CR28","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.968434","volume":"3","author":"I Adkins","year":"2014","unstructured":"Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P. & Spisek, R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 3, e968434 (2014).","journal-title":"Oncoimmunology"},{"key":"1819_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/cdd.2009.44","volume":"16","author":"L Galluzzi","year":"2009","unstructured":"Galluzzi, L. et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 16, 1093\u20131107 (2009).","journal-title":"Cell Death Differ."},{"key":"1819_CR30","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/10428190600581419","volume":"47","author":"M Girardi","year":"2006","unstructured":"Girardi, M. et al. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leuk. Lymphoma. 47, 1495\u20131503 (2006).","journal-title":"Leuk. Lymphoma."},{"key":"1819_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0092-8674(94)90169-4","volume":"76","author":"KA Hogquist","year":"1994","unstructured":"Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17\u201327 (1994).","journal-title":"Cell"},{"key":"1819_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/onc.2010.500","volume":"30","author":"I Martins","year":"2011","unstructured":"Martins, I. et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30, 1147\u20131158 (2011).","journal-title":"Oncogene"},{"key":"1819_CR33","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/sj.cdd.4402201","volume":"14","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14, 1848\u20131850 (2007).","journal-title":"Cell Death Differ."},{"key":"1819_CR34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1034\/j.1600-0625.2002.110609.x","volume":"11","author":"Y Tokura","year":"2002","unstructured":"Tokura, Y. et al. Augmentation of monocyte interleukin-8 production by psoralen\/UVA-treated CD4+ T cells. Exp. Dermatol. 11, 564\u2013572 (2002).","journal-title":"Exp. Dermatol."},{"key":"1819_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cdd.2013.73","volume":"21","author":"AQ Sukkurwala","year":"2014","unstructured":"Sukkurwala, A. Q. et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ. 21, 59\u201368 (2014).","journal-title":"Cell Death Differ."},{"key":"1819_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.cell.2018.03.015","volume":"173","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L., Vanpouille-Box, C., Bakhoum, S. F. & Demaria, S. SnapShot: CGAS-STING Signaling. Cell 173, 276\u2013276.e271 (2018).","journal-title":"Cell"},{"key":"1819_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/2040620713490316","volume":"4","author":"JW Hart","year":"2013","unstructured":"Hart, J. W., Shiue, L. H., Shpall, E. J. & Alousi, A. M. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther. Adv. Hematol. 4, 320\u2013334 (2013).","journal-title":"Ther. Adv. Hematol."},{"issue":"4","key":"1819_CR38","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jca.21698","volume":"34","author":"C\u00e9line Coppard","year":"2019","unstructured":"Coppard, C., et al. In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in GVHD: New insights in extracorporeal photopheresis. J Clin Apher 34, 450\u2013460 (2019).","journal-title":"Journal of Clinical Apheresis"},{"key":"1819_CR39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz, J. R. et al. ER Stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527\u20131538 (2015).","journal-title":"Cell"},{"key":"1819_CR40","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/emboj.2009.1","volume":"28","author":"T Panaretakis","year":"2009","unstructured":"Panaretakis, T. et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. Embo j. 28, 578\u2013590 (2009).","journal-title":"Embo j."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1819-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T12:19:02Z","timestamp":1671193142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1819-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["1819"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1819-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.G. provides remunerated consulting to OmniSEQ (Buffalo, NY, USA), Astra Zeneca (Gaithersburg, MD, USA), VL47 (New York, NY, USA) and the Luke Heller TECPR2 Foundation (Boston, MA, USA), and he is member of the Scientific Advisory Committee of OmniSEQ (Buffalo, NY, USA). R.L.E. is a shareholder in the Yale University startup company Transimmune AG. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written consent was obtained from all healthy volunteers involved in the study, which was approved by the Yale Human Investigational Review Board under protocol number 0301023636. Animal experiments were performed according to Yale Institutional Animal Care and Use Committee approved protocols, in agreement with the National Institutes of Animal Healthcare Guidelines. The Yale animal facility is accredited by the Association for Assessment of Laboratory Animal Care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"578"}}